Skip to content
Austin Top 50
Author:
ITM Isotope Technologies Munich SE
ITM Receives Complete Response Letter for ¹⁷⁷Lu-edotreotide (ITM-11)
August 10, 2026
EQPT Investors Have Opportunity to Lead EquipmentShare.com Inc Securities Lawsuit
August 5, 2026
BZAI Investors Have Opportunity to Lead Blaize Holdings, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
August 4, 2026
ITM Introduces Lumara Bio as Its New Oncology Therapeutics Division
July 27, 2026
CCOI Investors Have Opportunity to Lead Cogent Communications Holdings, Inc. Securities Fraud Lawsuit
July 24, 2026
ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs
July 7, 2026
ITM, Helmholtz Munich and the University of Münster Announce Updated Preliminary Phase 1 Data with ITM-31 in Glioblastoma Patients
June 29, 2026
VRRM Investors Have Opportunity to Lead Verra Mobility Corporation Securities Fraud Lawsuit
June 9, 2026
ITM Announces Phase 3 COMPETE Data Supporting Single-Timepoint Dosimetry for n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at SNMMI 2026
June 1, 2026
ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026
May 30, 2026
1
2
Next Page
→